ligand strength

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

106 documents for ligand strength

- Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn[R].
... is another transaction demonstrating the strength of the Ligand business model," said John Higgins, ...
- Business Wire
- October 10, 2011
- Ligand Presents Phase IIa Data on Captisol[R]-Enabled, Propylene Glycol-Free Melphalan at ASCO 2011.
..., potency, competitiveness, and the strength of Ligand's product portfolio. Actual events or re...
- Business Wire
- June 06, 2011
- Ligand Announces Successful Phase II Results for Captisol[R]-Enabled Propylene Glycol-Free Melphalan.
..., potency, competitiveness, and the strength of Ligand's product portfolio. Actual events or re...
- Business Wire
- November 02, 2011

- Ligand Presents Multi-Dose Phase I Data on Lead SARM Molecule LGD-4033 at the Endocrine Society Annual Meeting.
... trends in functional exercise and strength measures were consistent with anabolic activity. "...
- Business Wire
- June 06, 2011
- Ligand Presents First-in-Human Phase I Data on Lead SARM Molecule LGD-4033 at the International Congress of Endocrinology.
..., and competitiveness, and the strength of Ligand's product portfolio. Actual events or re...
- Business Wire
- March 29, 2010
- Ligand Reports Financial Results for Full Year and Fourth Quarter 2002; Total Revenues for the Year Increase 27%, Per Share Loss Decreases 35%.
... in other revenues, which underscores the strength of Ligand's corporate partners' portfolio of produ...
- Business Wire
- February 25, 2003
- Ligand Initiates Clinical Trial with the Selective Androgen Receptor Modulator LGD-4033, a Potential Treatment of Muscle and Bone Disorders.
... cortical bone formation rates, bone strength and bone density. LGD-4033 also suppressed bone tu...
- Business Wire
- June 17, 2009
- Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting.
... bone mineral density and bending strength (an indicator of resistance to fracture) in osteop...
- Business Wire
- November 20, 2009
- Ligand, Elan Agree On Early Conversion of $20 Million Note, Early Exercise of Ligand Warrants.
... in our 2002 goal to eliminate debt and strengthen our balance sheet," said Paul V. Maier, Ligand Sen...
- Business Wire
- April 01, 2002
- Ligand Pharmaceuticals Announces Second Quarter Results.
... effect of LGD-3303 on bone density and strength in osteopenic rats will be presented at the Americ...
- Business Wire
- August 08, 2007